6902: A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immune Deficiency (1968-2010)

Individuals with a past diagnosis of severe combined immune deficiency (including many cases of “leaky SCID”, Omenn syndrome, and reticular dysgenesis) who have undergone blood and marrow transplant, gene therapy, or enzyme replacement in the past may be eligible for 6902.  The purpose of 6902 is very similar to 6901, except 6902 is looking backwards at what has already been done in the past (compared to 6901 which is looking into the future).  Over 800 patients with SCID are expected to be enrolled on 6902.  This makes 6902 the largest study ever to describe outcomes for patients with SCID treated at many different hospitals around North America. 

One of the most important components of the 6902 study is the “cross sectional” study.  Patients who have received their treatments (BMT, gene therapy, enzyme replacement) many years ago are asked to come back to the hospital where they were treated.  During this visit, additional research blood work is drawn and information is gathered regarding long-term transplant outcomes such as infections, graft-versus-host disease, autoimmune diseases, and quality of life.  This will allow PIDTC researchers to better understand long-term outcomes from procedures that occurred many years ago (sometimes over 30 years ago) – something that is not possible at the present time with 6901.  This will help researchers to best design new treatments and clinical trials in the future for children with SCID.